RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives.
RedHill applies innovation, focus and a collective mindset of delivering on our promises in building a company primarily focused on U.S commercialization and development of drugs for gastrointestinal, infectious and oncologic diseases.
We have built an R&D pipeline of proprietary mid-to-late-stage clinical development drug candidates addressing major unmet medical needs.
Focused on driving increasing revenues, Talicia®, our FDA-approved treatment to eradicate H. pylori, is jointly commercialized in the U.S. by our dedicated and experienced commercial team with our partner, Cumberland Pharmaceuticals Inc.